Acurx Pharmaceuticals Inc (NASDAQ: ACXP)’s stock price has plunge by -14.23relation to previous closing price of 0.47. Nevertheless, the company has seen a -11.80% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-18 that Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Robert Shawah – Co-Founder and Chief Financial Officer David Luci – President and Chief Executive Officer Conference Call Participants Thomas Yip – H.C. Wainwright James Molloy – Alliance Global Partners Claire Acheson – Independent Investment Research Operator Greetings and welcome to the Acurx Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results and Business Update.
Is It Worth Investing in Acurx Pharmaceuticals Inc (NASDAQ: ACXP) Right Now?
The 36-month beta value for ACXP is also noteworthy at -1.48. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ACXP is 18.90M, and at present, short sellers hold a 2.40% of that float. The average trading volume of ACXP on March 19, 2025 was 360.13K shares.
ACXP’s Market Performance
The stock of Acurx Pharmaceuticals Inc (ACXP) has seen a -11.80% decrease in the past week, with a -45.31% drop in the past month, and a -54.25% fall in the past quarter. The volatility ratio for the week is 8.79%, and the volatility levels for the past 30 days are at 9.63% for ACXP. The simple moving average for the past 20 days is -32.65% for ACXP’s stock, with a -74.51% simple moving average for the past 200 days.
ACXP Trading at -43.34% from the 50-Day Moving Average
After a stumble in the market that brought ACXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.80% of loss for the given period.
Volatility was left at 9.63%, however, over the last 30 days, the volatility rate increased by 8.79%, as shares sank -45.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.69% lower at present.
During the last 5 trading sessions, ACXP fell by -11.80%, which changed the moving average for the period of 200-days by -83.77% in comparison to the 20-day moving average, which settled at $0.6025. In addition, Acurx Pharmaceuticals Inc saw -50.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACXP starting from Scodari Joseph C, who purchase 24,631 shares at the price of $1.01 back on Jan 06 ’25. After this action, Scodari Joseph C now owns 27,708 shares of Acurx Pharmaceuticals Inc, valued at $25,000 using the latest closing price.
Sailer Carl, the Director of Acurx Pharmaceuticals Inc, purchase 24,631 shares at $1.01 during a trade that took place back on Jan 06 ’25, which means that Sailer Carl is holding 137,183 shares at $25,000 based on the most recent closing price.
Stock Fundamentals for ACXP
The total capital return value is set at -18.41. Equity return is now at value -498.16, with -250.15 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.
Conclusion
In summary, Acurx Pharmaceuticals Inc (ACXP) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
